THERAPEUTICS AND HUMAN HEALTH PRODUCTS FOR BIOFILM PREVENTION & MICROBE CONTROL

The need for new antimicrobial drugs has increased tremendously because of the continual emergence of bacterial pathogens that are resistant to an array of drugs. This heightened resistance phenomenon poses a significant threat to the general public and, especially, to hospitalized patients. Biological Targets, Inc. (BTI) has identified and validated an essential anti-biofilm/anti-microbial drug target that has great potential to control clinically relevant bacterial and fungal pathogens.

The use of BTI’s target for development of an anti-infective involves a strategy that has not been exploited previously. The approach utilizes both the target and a related metabolic pathway for inhibiting or completely blocking the metabolic capacity of a pathogen. BTI’s anti-microbial target is attractive particularly for developing anti-biofilm products because b iofilms are involved in 65% of all human bacterial infections. They also are major contaminants of implantable biomedical devices. In addition, BTI’s target has great potential to control bacterial and fungal pathogens of agricultural and industrial importance.  BTI’s new anti-microbial target is absent in humans and animals, making it attractive for the development of safe broad-spectrum antimicrobial products.

Products

Molecular Targets for Insecticide Development

Mosquito Targets

Bt-based Biopesticides for Insect and Nematode Control

Fire Ant, Mosquitoes, Cotton Insects

Beneficial Biofilm Products for Soil Improvement and Reclamation

RECLAFIL™

Therapeutics and Human Health Products for Control of Biofilms and Microbes

Read more...